Martin Stuschke
Overview
Explore the profile of Martin Stuschke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
3951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin X, Qiu Y, Soni A, Stuschke M, Iliakis G
Mol Ther Oncol
. 2025 Feb;
33(1):200934.
PMID: 39968096
The development of poly (ADP-ribose) polymerase inhibitors (PARPis) is widely considered a therapeutic milestone in the management of BRCA1/2-deficient malignancies. Since a growing number of cancer treatment guidelines include PARPis,...
2.
Jabbarli L, Fiorentzis M, Rating P, Schmidt B, Biewald E, Guberina N, et al.
Radiat Oncol
. 2025 Feb;
20(1):22.
PMID: 39940039
Objective: Preservation of visual acuity remains a challenging issue after globe sparing therapy of large uveal melanoma. The aim of our study was analyzing the functional outcome after brachytherapy with...
3.
Guberina M, Stuschke M, Fluhs D, Jabbarli L, Kiefer T, Biewald E, et al.
Radiother Oncol
. 2025 Feb;
205:110775.
PMID: 39922315
Background: Dose-response relationships for optic neuropathy and optic nerve atrophy after brachytherapy for posterior uveal melanoma were poorly defined from previous studies. Here, the outcome differences were analyzed in dependence...
4.
Keyl J, Keyl P, Montavon G, Hosch R, Brehmer A, Mochmann L, et al.
Nat Cancer
. 2025 Jan;
6(2):307-322.
PMID: 39885364
Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to...
5.
Baldes N, Grapatsas K, Dorr F, Menghesha H, Schuler M, Welt A, et al.
J Thorac Dis
. 2024 Nov;
16(10):7182-7191.
PMID: 39552847
Background And Objective: Advanced breast cancer (BC) can involve the chest wall through local invasion by the primary tumor, locoregional recurrence, hematogenous metastasis, or sternum infiltration of the internal mammary...
6.
Elsayad K, Guenova E, Fournier B, Fernandes C, Clementel E, Papadavid E, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
121(4):1006-1010.
PMID: 39549760
Purpose: We aim to determine the current treatment patterns and recommendations among physicians for cutaneous lymphomas and to identify the types of skin lymphomas for which existing radiation regimens need...
7.
Watanabe M, Fendler W, Grafe H, Hirmas N, Hamacher R, Lanzafame H, et al.
Ann Nucl Med
. 2024 Oct;
39(3):255-265.
PMID: 39443386
Objective: FAPI-PET/CT exhibits high tumor uptake and low background accumulation, enabling high-sensitivity tumor detection. We compared the diagnostic performance of Ga-FAPI-46 PET/CT plus contrast-enhanced CT (CE-CT), F-FDG PET/CT plus CE-CT,...
8.
Jannusch K, Umutlu L, Kirchner J, Bruckmann N, Morawitz J, Herrmann K, et al.
J Nucl Med
. 2024 Oct;
65(12):1855-1861.
PMID: 39389629
Our rationale was to investigate whether F-FDG PET/MRI in addition to (guideline-recommended) conventional staging leads to changes in therapeutic management in patients with newly diagnosed breast cancer and compare the...
9.
Wiesweg M, Kuter C, Schnorbach J, Keyl J, Metzenmacher M, Cvetkovic J, et al.
Int J Cancer
. 2024 Sep;
156(4):776-787.
PMID: 39319506
Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal...
10.
Mavroeidi I, Romanowicz A, Haake T, Wienker J, Metzenmacher M, Darwiche K, et al.
Theranostics
. 2024 Sep;
14(14):5400-5412.
PMID: 39310095
Positron Emission Tomography (PET) using the somatostatin receptor 2 (SSTR2)-antagonist satoreotide trizoxetan (Ga-SSO120) is a novel, promising imaging modality for small-cell lung cancer (SCLC), which holds potential for theranostic applications....